X4 Pharmaceuticals Inc
XFOR
Company Profile
Business description
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Contact
61 North Beacon Street
4th Floor
BostonMA02134
USAT: +1 857 529-8300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
143
Stocks News & Analysis
stocks
WiseTech result disappoints, but the future looks bright
Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
stocks
WOW earnings: Woolworths losing market share, but will catch up to Coles
Woolworths have had a soft start to a challenging year, but Morningstar analyst believes it will eventually catch up to its main competitor.
stocks
Chart of the Week: Largest share price falls during earnings
Opportunities arise when the market overreacts, and good quality companies are mispriced.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,241.10 | 0.50 | -0.01% |
| CAC 40 | 7,762.60 | 18.67 | 0.24% |
| DAX 40 | 24,039.92 | 6.29 | -0.03% |
| Dow JONES (US) | 45,573.14 | 7.91 | 0.02% |
| FTSE 100 | 9,216.82 | 38.68 | -0.42% |
| HKSE | 24,998.82 | 202.94 | -0.81% |
| NASDAQ | 21,700.56 | 110.42 | 0.51% |
| Nikkei 225 | 42,828.79 | 308.52 | 0.73% |
| NZX 50 Index | 12,903.08 | 41.24 | 0.32% |
| S&P 500 | 6,495.76 | 14.36 | 0.22% |
| S&P/ASX 200 | 8,980.00 | 9.50 | 0.11% |
| SSE Composite Index | 3,843.60 | 43.25 | 1.14% |